Clinical and Radiographic Outcomes of the JointMedica Custom-Made Resurfacing Device
Launched by JOINTMEDICA INC. · Jul 23, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a custom-made hip resurfacing device called the JointMedica Custom Resurfacing Implant, which is designed to help reduce pain and improve hip function in adults who need a hip joint replacement but don’t have other suitable options. The device is made of metal and a special durable plastic, with parts that attach to the thigh bone and hip socket. The study aims to see how well this device works in real-life patients by looking at how long the hip parts last, how well they stay in place, if patients need any additional surgeries, and if there are any serious side effects related to the device. Researchers will also ask patients about their hip function and pain levels using simple questionnaires.
To join the study, participants must be 21 years or older and have already had this specific hip resurfacing device implanted between September 2020 and January 2025. There are no other restrictions for joining. If you take part, you can expect regular follow-ups for up to two years to check the condition of your hip implant through X-rays and questionnaires about your hip health. This study is not yet recruiting, but it aims to gather important information to help doctors and patients understand the safety and effectiveness of this custom hip implant in everyday use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 21 or above at the time of the surgery.
- • Have had the JointMedica Custom-Made Hip Resurfacing device implanted between September 2020 to January 2025
- • Written informed consent given by subject
- Exclusion Criteria:
- • There is no exclusion criteria for this study
About Jointmedica Inc.
JointMedica Inc. is a pioneering clinical trial sponsor focused on advancing innovative medical solutions to enhance patient care and outcomes. With a commitment to rigorous scientific research and ethical standards, JointMedica collaborates with healthcare professionals and institutions to develop and evaluate cutting-edge therapies across various therapeutic areas. The company leverages state-of-the-art technology and a patient-centric approach, ensuring that clinical trials are designed to meet the highest standards of safety and efficacy. By fostering partnerships and engaging stakeholders, JointMedica aims to accelerate the development of transformative healthcare solutions that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Bromsgrove, United Kingdom
Patients applied
Trial Officials
Ronan Treacy
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported